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Abstract
Background: Global health partnerships have grown rapidly in number and scope, yet there has been less emphasis 
on their evaluation. Gavi, the Vaccine Alliance, is one such public-private partnership; in Gavi-eligible countries 
partnerships are dynamic networks of immunization actors who work together to support all stages and aspects of 
Gavi support. This paper describes a conceptual framework – the partnership framework – and analytic approach for 
evaluating the perceptions of partnerships’ added value as well as the results from an application to one case in Uganda. 
Methods: We used a mixed-methods case study design embedded in the Gavi Full Country Evaluations (FCE) to 
test the partnership framework on Uganda’s human papillomavirus (HPV) vaccine application partnership. Data from 
document review, interviews, and social network surveys enabled the testing of the relationships between partnership 
framework domains (context, structure, practices, performance, and outcomes). Topic guides were based on the 
framework domains and network surveys identified working together relationships, professional trust, and perceptions 
of the effectiveness, efficiency, and legitimacy of the partnership’s role in this process. 
Results: Data from seven in-depth interviews, 11 network surveys and document review were analyzed according 
to the partnership framework, confirming relationships between the framework domains. Trust was an important 
contributor to the perceived effectiveness of the process. The network was structured around the EPI program, who 
was considered the leader of this process. While the structure and composition of the network was largely viewed 
as supporting an effective and legitimate process, the absence of the Ministry of Education (MoE) may have had 
downstream consequences if this study’s results had not been shared with the Ministry of Health (MoH) and acted 
upon. The partnership was not perceived to have increased the efficiency of the process, perhaps as a result of unclear 
or absent guidelines around roles and responsibilities.
Conclusion: The health and functioning of global health partnerships can be evaluated using the framework and 
approach presented here. Network theory and methods added value to the conceptual and analytic processes and we 
recommend applying this approach to other global health partnerships to ensure that they are meeting the complex 
challenges they were designed to address. 
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Implications for policy makers
• Policy-makers can use the partnership framework and network mapping to understand the actors in the partnerships that affect their work.
• Based on an understanding of the relevant stakeholders, policy-makers, and those who support them can work to ensure that all relevant 
government and non-government stakeholders are represented in the process. 
• Policy-makers and those who support them can strengthen partnerships and processes by ensuring sufficient coordination mechanisms, 
including the existence of terms of reference or a partnership coordinator. As partnerships grow they require additional investment in 
coordination. 
Implications for the public
The public, and particularly the health of the public, is shaped by policies that are developed and implemented by networks of actors, where the ability 
to work together to develop or implement a government policy depends on who is involved and how they are connected. This study shows that the 
structure and quality of connections between people involved in immunization policy in Uganda affected their ability to work together effectively, 
efficiently, and with a sense of legitimacy. By improving the evaluation of partnerships using the partnership framework and approach, this research 
can help policy-makers make better policies by ensuring that the right people are involved, and better policies will ultimately improve the quality of 
life for all citizens. 
Key Messages 
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Background
As the size and scope of the global health agenda has grown 
in the past decades, so too has the need to leverage a greater 
number and type of actors and their resources, leading to the 
rise of “Global Health Public-Private Partnerships,” (GHPPPs) 
or “Global Health Initiatives.” The World Health Organization 
(WHO) Maximizing Positive Synergies Collaborative Group 
counted 100 such entities that participate in a range of 
activities related to global health decision-making, funding, 
implementation and technical assistance at global, national, 
and sub-national levels.1 United Nations (UN) agencies and 
other international organizations have signaled their support 
for GHPPPs, perhaps, as suggested elsewhere, to fill perceived 
gaps in their own mandate and expertise.2 “Partnership” is a 
Sustainable Development Goal, indicating global recognition 
for the partnership approach to development.3 
A review of GHPPPs suggests they are particularly effective at 
getting specific health issues onto national and international 
agendas, mobilizing additional funds for these issues, 
stimulating research and development, improving access to 
cost-effective health interventions, strengthening national 
policy processes and content, augmenting health service 
delivery capacity, and establishing international norms and 
standards.4 This list of strengths simultaneously signals the 
vertical, disease-specific nature of GHPPPs – a commonly 
reported flaw.1 Other observed challenges with this model 
include their propensity to skew national priorities, poor 
transparency and accountability standards, insufficient use 
and harmonization with country systems, leading to waste, 
and sub-standard approaches to managing human resources 
within the partnership.4
Gavi, the Vaccine Alliance, formerly known as the Global 
Alliance for Vaccines and Immunizations is an example 
of an early adopter of the global health partnership 
governance and business model. Founded in 1999 as a 
public-private partnership, the Alliance brings together 
country governments, UN agencies, vaccine manufacturers, 
philanthropic foundations, non-governmental organizations 
(NGOs) and research institutes to achieve the Alliance’s 
mission of saving lives and protecting people’s health by 
increasing access to immunization in poor countries. Each 
partners’ activities are mutually agreed upon at the global 
level and outlined in an annual business plan,5 with the Gavi 
Secretariat serving as a “steward for the Alliance” and the Gavi 
Alliance Board ultimately endorsing all decisions.6 While the 
Alliance has been credited with accelerating the adoption and 
increasing the coverage of new and under-utilized vaccines,7,8 
its partnership approach has not been without growing pains 
and critiques. The first independent evaluation of the Alliance 
highlighted the issue of unclear roles and responsibilities but 
contrasted this with the partnership’s ability to “allow quick 
decision-making, innovation and flexibility, and open debate 
and self-assessment.”9 The second Gavi evaluation reported 
the benefits of a lean organizational structure on efficiency 
and effectiveness.10 Yet, Naimoli6 reported that in the case of 
gavi’s health systems strengthening (HSS) grants, inadequate 
explication of roles and responsibilities, a lack of transparency 
and trust, and differing ideologies were some challenges noted 
by participants at all levels of the Alliance.
As the Gavi strategy has evolved to include strategic goals 
related to coverage and equity as opposed to simply new vaccine 
introductions,9,10 so too has the recognition that partners 
must bring a growing diversity of skills and approaches to the 
partnership.11,12 This is certainly true for the case of Uganda, 
whose immunization system performance is gradually 
improving following the re-introduction of Gavi support 
in 2012 and thus the reorganization of its immunization 
program and partnership, and where the efficient allocation 
and coordination of partners’ comparative advantages will 
be essential to supporting national and global goals.13 Gavi’s 
2015 announcement of a new structure for coordinating and 
managing Gavi Alliance partners — the Partners’ Engagement 
Framework14 — will replace the Gavi Business Plan in an effort 
to ensure country-centric processes and increase the relevance 
of partners’ activities; it is also a reflection of the broader 
growth in the diversity and decentralization of partnerships 
and networks for global health.5,14 This paper presents a 
case study of an Alliance partnership in Uganda prior to the 
introduction of the Partners’ Engagement Framework, but 
which may serve as a useful baseline.
This paper outlines an approach to evaluating the 
effectiveness, efficiency, and legitimacy of global health 
partnerships with an illustration from the Full Country 
Evaluations (FCE) commissioned by the Alliance. The FCE 
is a 4-year prospective evaluation of Alliance support in four 
countries which ultimately aims to connect inputs, outputs, 
outcomes and the impact of Gavi support while learning 
lessons about the process and areas for improvement.15 A 
key evaluation question is centered on the role and effect of 
the Alliance partnership on decision-making, planning, and 
implementation of financial and technical support. This study 
builds on existing evaluations of the Alliance partnership1,4,6,9,10 
by introducing a framework that illustrates the theoretical 
linkages from inputs to outcomes — effectiveness, efficiency, 
and country ownership — of partnership-led processes 
through the application of mixed-methods data collection and 
analysis. The results of this study will be of particular salience 
as the Partners’ Engagement Framework is implemented 
and may serve as a baseline description of the state of Gavi 
partnership in one priority country. 
The aims of this paper are two-fold. First, we describe in 
detail how to design and implement an evaluation of health 
partnerships, drawing on a specific theoretical framework 
(the ‘partnership framework’) and social network analysis 
(SNA). Second, we apply the partnership framework to a 
specific national level case of an immunization partnership 
to demonstrate how the framework can be used to describe 
and relate partnership domains to perceptions of outcomes 
in the process, and to assess the feasibility and usefulness 
of this approach. The case study is the process surrounding 
the Government of Uganda’s application for Gavi funding 
for national introduction of the vaccine against human 
papillomavirus (HPV). The paper closes with a discussion 
of the implications of the partnership evaluation approach 
for other global health partnerships and partnerships more 
generally.
Appropriately Defining and Measuring Partnership Practice 
and Structure
A broad range of literature addresses partnership definition, 
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practice, and measurement, including concepts from 
public administration, organizational science, and network 
analysis.16-22 The FCE evaluation team integrated these 
concepts to develop and apply a new conceptual framework to 
measure the partnership approach’s contribution to national 
immunization processes. In doing so, the evaluation responds 
to two gaps in current partnership evaluation practice: 
the tendency to ignore the inner workings of partnership 
relationships, and limited use of available analytic tools to 
measure and describe partnership structure. Partnerships 
are composed of individuals and the relationships between 
them, making it essential to understand the inner workings 
of a partnership to influence the overall functioning of the 
partnership. Despite the availability of SNA tools and methods, 
the increasing number of global health partnerships has not 
been matched by a corresponding increase in measurement 
of these networks. This paper provides a framework whereby 
stakeholders or decision-makers can evaluate their own 
partnerships to ensure that there is an added value of the 
existing partnership in terms of efficiency, effectiveness, and 
country ownership. 
A Partnership Framework for Looking Inside the Black Box
We defined partnership according to existing definitions 
from public administration and governance, in which 
“partnerships” — sometimes called “alliances” or “networks” 
— are dynamic relationships between diverse actors, often 
representing different organizations, who share mutually 
agreed objectives and work together to achieve a common 
goal.17,23,24 Measurable characteristics of partnerships can be 
contrasted with other governance or organizational structures 
such as contractual or direct implementation models,16,25 
which have been the historic norm in global health and 
still constitute the vast majority of decision-making and 
implementation processes (see Table 1). Unlike contractual 
relationships where roles and responsibilities are demarcated 
and enforceable and where goals are often set by one party and 
communicated vertically to another, partnerships are defined 
by flexible and dynamic allocation of roles and responsibilities 
and mutual decision-making and goal-setting. Partnerships 
are expected to achieve better results, more efficiently, with 
greater legitimacy or country ownership.16 
We reviewed the literature on partnership evaluation to 
identify and assess existing frameworks or approaches to 
measuring partnership. Based on this review, we selected a 
conceptual framework described by Brinkerhoff16 – one of the 
only frameworks describing the holistic set of possible factors 
from an evaluation perspective and how they inter-relate to 
lead to added value. Further, this framework has been applied 
to multiple cases of development partnerships.26-29
The framework suggests five dimensions to evaluate, 
proposing causal relationships between them: context and 
partnership prerequisites, partnership structure, partnership 
process, and outcomes, or the added value of the partnership 
(see Figure 1). The context in which the partnership functions 
is determined by contextual factors and pre-requisites [1], 
which may include characteristics of the issue or process, 
the existence of champions, a history of partnerships and 
power-sharing mechanisms, and/or the broader political 
environment. Partnership structure [2] is the overall 
composition of the partnership, the nature of connections 
between members, and their respective functions. Partnership 
process is a function of partner performance [3] and 
partnership practice [4]. Partner performance describes each 
partner’s comparative advantage, roles and responsibilities, 
and their effectiveness in fulfilling these roles. Partnership 
practice [4], are behaviors and mechanisms among member 
organizations within a partnership that enhance or diminish 
the value of a partnership on the process.16 Partnership 
practice in turn contributes to outcomes, or the added value 
of the partnership. We chose to define and measure added 
value in line with the FCE’s broader evaluation aims and the 
focus on effectiveness, efficiency and country ownership 
[5],15,30 and measured perceptions of these outcomes using a 
survey tool proposed to assess and strengthen partnerships 
using network analysis.31 The effectiveness of the partnership 
is determined based on the completeness, quality, relevance, 
and responsiveness of the process. Efficiency is based on the 
timeliness, responsiveness, costs-savings, and nimbleness of 
the partnership. We adapted the concept of ‘legitimacy’ to be 
more specific to Gavi’s core principle of ‘country ownership.’32 
Country ownership is determined based on the level of 
autonomy, participation, transparency and satisfaction, 
adherence to good governance principles, and the legitimacy 
and sustainability of the partnership. Previous applications 
of the Partnership Framework have drawn on qualitative or 
archival data to develop case descriptions.29 We expanded this 
approach to include social network data and triangulation 
across all data sources.
Measuring and Describing Partnership Structure
A second gap in the existing empirical research on partnership 
pertains to the limited use of appropriate tools and analytic 
methods to measure and describe structure. Structure, 
which lies at the heart of what differentiates a partnership 
model from other organizational, governance or business 
Table 1. Partnership vs. Contractual Relationshipa
Partnership Relationship Contractual Relationship
Characteristics of relationship Key words: trust, horizontal, mutual, shared Key words: hierarchical, vertical
Who sets goals/objectives Mutual, shared and agreed goal among partners Contracting organization sets goals/objectives
Decision-making
Mutual decision-making process and/or potential to 
influence decisions
Contracting organization makes decision
Accountability Reciprocal accountability on outcomes
Unilateral accountability on outputs by contracted to 
contractor
Organizational identity
The assignment of roles and responsibilities clearly 
reflects competitive advantage of member organizations
The assignment reflects contracting organization’s interests 
and purpose in engaging other member organizations
a Reference 16.
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models, is described in the existing partnership literature as 
“flat,” “horizontal,” or “decentralized” (see again Table 1).16,20 
We argue that the utility of the partnership framework, and 
particularly its ability to measure and understand partnership 
structure, could be improved through the systematic 
application of SNA concepts and tools. 
Social network theory, broadly, suggests that the behaviors 
and decisions of nodes — individuals, organizations, or any 
other unit — are determined by those nodes’ relationships 
with other nodes, as well as the larger structure created 
by the entirety of the relationships.33 In policy and 
organizational sciences, the structure of individuals or 
organizations in decision-making, management, planning, 
and implementation have been correlated with outcomes 
such as innovation, evidence exchange and use, efficiency, 
knowledge transfer, and learning.18-21,34-36 Structure, in this 
sense, is empirically measurable and frequently represented 
by metrics such as density (ie, the proportion of possible ties 
that exist in the network), centralization (ie, the proportion of 
ties that go to one focal actor), and diversity (ie, the proportion 
of ties that are outside- versus within-group).33 The systematic 
measurement of these metrics and their linkage through the 
framework to the Alliance objectives is a methodological 
innovation which will hopefully support efforts to evaluate 
the Alliance partnership model in order to enable it to achieve 
its intended outcomes moving forward. 
Methods
In this section, we elaborate on the evaluation design and 
implementation so that it can be easily replicated. We provide 
sample data collection tools in Supplementary Files 1 and 2. 
Design
Applying the partnership framework required a mixed-
methods case study design37 embedded in an ongoing 
prospective evaluation of Alliance support (the FCE).15 
Among the four FCE countries, Uganda was chosen as the 
initial case country to implement the partnership analysis 
because of local interest and the recent completion of a 
potential case – the development of the funding application 
to the Alliance for HPV vaccine introduction at the national 
Figure 1. Partnership Analysis Framework.
level. In the partnership analysis approach, the ‘case’ can be 
defined as a process with a specified outcome of the process, 
for example an application for new vaccine support, resulting 
in a submission to the Alliance; or the planning process 
culminating in the launch of a new vaccine. Defining the 
case as process facilitates cross-country comparisons and 
encourages empirical identification of the network of actors 
who have participated. It ensures that the outcomes (Figure 
1, Box 5) are well-defined and measurable, thus, enabling 
attribution. 
The HPV vaccine application process was chosen as a suitable 
case because of its timeliness in relation to planned data 
collection and the potential of applying lessons learned to 
both the ongoing implementation of HPV vaccine in Uganda 
as well as to other new vaccine applications in Uganda and 
elsewhere. In addition, it was of theoretic and programmatic 
interest to understand how a partnership around HPV 
vaccine, which targets adolescent girls to prevent cervical 
cancer, might involve a different group of stakeholders than 
traditional childhood vaccines. As the Partners’ Engagement 
Framework moves to include ‘expanded’ partners,14 the 
process and outcomes of adding new partners is of particular 
relevance. Finally, although certain immunization activities 
(ie, vaccine implementation) involved partners spanning 
administrative levels and jurisdictions, a national level 
process was chosen for ease of access to potential respondents 
and data collection. 
 
Data Collection
Data collection included document review and in-depth 
interviews, including a structured network survey, with key 
informants. The document review component informed the 
development of topic guides and supported the identification 
of initial interview respondents. Documents included the 
final report of Uganda’s HPV vaccine demonstration project,38 
minutes of application meetings, the application submission 
to Gavi,39 and Gavi’s decision letter. 
In-depth semi-structured interviews were conducted with 
individuals involved in the HPV vaccine application process. 
Respondents were identified based on the local research 
team’s in-depth knowledge of the process, and augmented 
by document review. Interviewers, who were members of 
the local FCE research teams, followed topic guides based on 
the partnership framework domains (see Supplementary File 
1 for sample topic guide). The aim of the interview was to 
elicit the respondent’s perception of the overall application 
process, as well as of constructs within each domain in order 
to test the relationships between the constructs and domains. 
All interviews were conducted in Kampala, the capital city of 
Uganda. Interviews lasted on average 45 minutes. Notes were 
taken during the interview and were expanded immediately 
following the interview.
During the interviews, the research team also administered 
a structured network survey adapted from Provan et al31 
(see Supplementary File 2 for sample survey). This survey 
was administered orally at the start of the interview. One 
attempt to administer it over email was unsuccessful and 
required visiting that respondent in person; attempts to leave 
it to the end of the interview resulted in rushing through it, 
which is a particular challenge when interviewing policy-
1. Contextual factors and pre-requisites




4. Partnership Practices 3. Partner Performance
2. Partnership Structure
GAVI Assistance Implementation Process
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makers and other policy elites. The survey began by asking 
the respondent to provide the names of the individual people 
he or she worked with on the HPV vaccine application. 
This open-ended ‘name generator’ encourages the empirical 
identification of the true actors in a network, as opposed to 
a roster approach (ie, a list of names), which might bias the 
network towards who is named in formal documentation.33 
We chose to define our units of survey observation, as well as 
the node level units of analysis in the networks, as individuals 
rather than organizations. This decision was based on the local 
research team’s in-depth understanding of partner dynamics 
and previous policy network mapping studies that suggested 
that decision-making was largely relational on an individual 
level, and that personal behaviors and attributes should not 
be ignored.35 
For each name provided, the respondent was also asked 
whether they shared information with that person during 
the HPV vaccine application process, how many years they 
have known that person, and their level of professional trust 
for that person. Professional trust was defined using the 
following prompt: “When we say ‘trust,’ we mean can you trust 
that organization to keep their word, to do a good job, and to 
respond to your organization’s needs?” and rated on a scale of 
1-4 (little trust – high trust; see survey Supplementary File 2 for 
more details). The question of trust often led to open-ended 
responses which were recorded and probed on. Interviewers 
used a fluid approach where they probed on responses during 
the survey to discuss related domains in the interview topic 
guide. Following the network survey, respondents were asked 
to indicate their perceptions of the effectiveness, efficiency, 
and country ownership of the partnership. To do this, the 
interviewers read a list of statements adapted from Provan 
and Milward18 and were asked to indicate “occurred” or 
“did not occur” for each. For example, “Planned activities 
were executed with greater quality” was one indicator of 
effectiveness; “Reduction in financial cost of process” was one 
indicator of efficiency, and “Increased legitimacy of decisions 
made” was one indicator of country ownership. Negative 
statements (eg, “Unnecessary management burden on my 
organization”) were also included (see Supplementary File 2 
for complete list of questions). Interviewers found that this 
component of the survey was easier to complete if they passed 
the survey instrument to the respondent to read and self-
administer. Again, interviewers recorded verbal comments 
and open-ended responses and probed where appropriate. 
The survey also included questions about the respondent’s 
basic job and demographic characteristics, which were 
completed by the research team prior to the interview to the 
extent possible. Job and demographic characteristics were 
also completed, to the extent possible by searching meeting 
minutes or the Internet, for identified network members who 
were not surveyed. 
Sampling Procedure and Boundary Definition
A ‘snowball,’ or respondent-driven sampling, approach was 
used to identify respondents for this study.33 This approach 
was used because it encourages the empirical identification 
of true actors in a network as opposed to providing a list of 
people to the respondents which might bisas the network. 
Due to the prospective nature of the evaluation, the team 
identified the initial respondents through document review 
and participant observation during planning meetings. The 
goal of this process was to identify a sub-set of individuals 
who were likely to be central to the network without being 
overly homogenous or closed as a group.
Using an open name generator, names of individuals 
mentioned in the interviews were added to a master list 
of network members and these were then approached for 
an interview. In this approach to defining a network — as 
opposed to the roster approach which assumes a fixed and 
known member list — the researcher must define a boundary 
for data collection but attempt to capture the entire census 
of network members within that boundary. We chose to stop 
including new names (ie, the network boundary) when a 
round of names elicited fewer new names than the previous 
round. This is a common decision point for dispersed 
networks, such as policy networks, as it suitably limits bias 
while not overtaxing resources.40 
Data Analysis
The research team read the qualitative interview notes 
together and coded text segments by hand according to a 
pre-determined coding structure based on the framework 
categories. Additional codes included codes for interactions 
between categories, and the application process for inactivated 
poliovirus vaccine (IPV) which had occurred more recently 
than the HPV vaccine application process and was mentioned 
often during interviews. The team read the coded text 
segments and wrote a memo for each theme summarizing key 
interpretations and findings. 
Immediately following interviews, network data were entered 
in matrix form in a MS Excel workbook. Names were entered in 
rows and columns and the existence of a working relationship 
was entered in each node-alter cell, weighted by the reported 
trust score. A second matrix recorded information exchange 
ties, entered as binary (0 = no tie was reported; 1 = a tie was 
reported). Respondent attributes and perceived outcomes 
were entered in a third worksheet, and descriptive analyses 
performed in Stata.
The two resulting network sociomatrices were imported into 
UCINET software41 where the maximum value of two ties 
was taken in cases of asymmetry. Density, centralization, and 
degree centrality were computed based on existing algorithms; 
a dichotomized version of the working relationship network 
was also analyzed. Network maps were produced for the 
networks using NetDraw.42
The Case of Applying to Gavi for the Human Papillomavirus 
Vaccine Support
Uganda National Expanded Program on Immunization 
(UNEPI) is responsible for immunization under the Ministry 
of Health (MoH) in Uganda and is headed by the Assistant 
Commissioner of Health Services also known as the Expanded 
Program on Immunization manager (EPI manager). UNEPI 
is situated in the Department of National Communicable 
Diseases Control (NDC) within the Directorate of Clinical 
and Community Services. The UNEPI program is responsible 
for policy, standards and priority setting, capacity building, 
coordinating with other stakeholders and partners, resource 
mobilization, monitoring, and technical support supervision 
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to districts.43 UNEPI links with other MoH departments 
and divisions through Technical Working Groups as well as 
Senior and Top Management committees. EPI activities are 
organized during monthly technical committee meetings 
consisting of EPI country partners led by the EPI manager.
EPI has various partners including (1) Public partners such as 
National Medical Stores (NMS), district administrations and 
health facilities; (2) Development partners such as United 
Nations Children’s Fund (UNICEF), the WHO, and bilateral 
donors; (3) International non-governmental organizations 
(INGOs) such as PATH, SABIN Vaccine Institute, African 
Field Epidemiology Network (AFENET), and Maternal and 
Child Health Integrated Program (MCHIP).
Uganda has benefited from Alliance support since 2001 with 
the introduction of hepatitis B vaccine and immunization 
services support (ISS); since that time it has introduced 
Haemophilus influenzae (Hib) vaccine and pneumococcal 
conjugate vaccine (PCV), and utilized cash support for 
injection safety (INS) and HSS windows, receiving a total of 
$190.6M in Alliance funds to date. Gavi support to Uganda 
was suspended in 2006 following financial irregularities and 
was re-commenced in 2012 when those irregularities were 
resolved. 
In Uganda, cervical cancer accounts for 40% of all cancers 
recorded by the cancer registry, and over 80% of women with 
cervical cancer are diagnosed with advanced disease.44 Cervical 
cancer is caused by HPV which is a sexually transmitted 
infection. In Uganda, the annual age-standardized incidence 
of cervical cancer is estimated at 44.4 per 100 000 women per 
year and age-standardized mortality rate estimated at 27.2 
per 100 000 women per year (2012 estimates).45 From WHO 
projections, deaths are predicted to increase by nearly 80% by 
2030 in mostly low- and middle-income countries, Uganda 
inclusive.44 Fortunately, the disease can easily be prevented 
through HPV vaccinations, screening and treatment. A 
vaccine to prevent cervical cancer was approved and licensed 
in the United States in 2004 and in Uganda in 2007.
In order to benefit from Alliance support for HPV vaccine, 
countries are required to demonstrate their ability to deliver 
HPV vaccines to adolescent girls prior to application for 
national rollout. Uganda was among the countries selected by 
PATH to undertake an HPV Vaccines project along with India, 
Peru, and Vietnam. The project in Uganda was implemented 
by UNEPI of the MoH with technical support from PATH, and 
operations research was conducted by the Child Health and 
Development Centre (CHDC) and PATH. The demonstration 
project aimed at assessing the feasibility, acceptability and 
cost of delivering HPV vaccine. The demonstration project 
was initially implemented in two selected districts in 2008, 
each testing a different approach, but later scaled up to 12 
additional districts in 2009. In Nakasongola district, delivery 
of HPV vaccine was tested through the biannual Child Days 
Plus (CDP) approach and the target population was girls 10 
years of age. In Ibanda district, a school-based approach was 
used and the target population was based on school grade 
(Primary 5) or 10 years of age for girls who were not attending 
school.
The demonstration was considered successful and the 
accompanying report indicated that the HPV vaccine was 
highly acceptable in communities and that implementation 
was feasible.38 A coverage survey in 2009 showed 88.9% 
coverage with the school-based delivery strategy and 60.7% 
coverage with the CDP delivery strategy.38 Based on the 
success in the two districts, the demonstration project shifted 
to using a combined approach of integrating the CDP with 
school-based immunization, and HPV vaccine immunization 
was extended to 12 additional districts in 2012. The new 
combined approach targeted all girls in Primary 4, regardless 
of age, and 10-year-old girls who were not in school. 
Vaccination of the first cohort of girls in the 12 new districts 
began in September 2012, the second dose was administered 
in November 2012, and the third dose between March and 
August 2013.
Its success provided evidence to the Government of Uganda 
about when and how best to introduce the HPV vaccine 
country wide prior to application for national rollout as this 
was a Gavi requirement. The HPV vaccine delivery model 
decided upon then however, has changed due to its feasibility 
and financial sustainability. Following the successful 
demonstration, Uganda then made a decision to apply to Gavi 
for national introduction of HPV vaccine. The application 
for national introduction of HPV vaccine was prepared 
between May and September 2013. The initial application was 
submitted by the Government of Uganda in September 2013 
and was approved by Gavi in March 2014.
Results
Summary of Descriptive Statistics
The team conducted key informant interviews (KIIs) with 
seven individuals involved in the HPV vaccine application 
process between August and October 2014. An additional 
four network surveys were administered without an in-depth 
interview, totaling 11 surveys. Respondents were all based 
at the national level and represented the MoH and partner 
organizations (see Table 2).
Through the snowball sampling approach we identified a 
total of 39 individuals who participated in the HPV vaccine 
application process. Actors in this network had an average of 
2.8 ties and reported moderate-high levels of trust for each 
other (Table 3). The low density score is likely explained by 
incomplete data collection.
Table 4 shows respondents’ mean level of agreement with 
each of the potential benefits statements. Eighty-four percent 
of 11 respondents agreed with statements that linked the 
partnership with increased country ownership, while 79% 
Table 2.  Organizational Affiliations of Identified Actors










Abbreviations: MoH, Ministry of Health; CSO, civil society organization; 
NGO, non-governmental organization.
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considered it to have improved effectiveness, and 63% 
thought it improved efficiency. When assessing potential 
drawbacks of the partnership, 25% of respondents agreed 
with the statement that the partnership led to an “unnecessary 
management burden on my organization” (see Table 4).
Interpreting the Data Through the Partnership Framework
We found that the partnership framework was useful in 
drawing out relationships between variables. We note three 
key findings relating the HPV vaccine application partnership 
to observed outcomes. First, trust was identified in qualitative 
and quantitative findings as being an important contributor 
to the perceived effectiveness of the process. Second, network 
mapping identified the absence of the ministries of education 
and finance during the application meetings, which may 
explain observed delays in the planning process after the 
HPV vaccine grant had been received. Third, respondents 
perceived the partnership to be only moderately efficient, 
which might be explained by the lack of clear guidelines or 
terms of reference around roles and responsibilities. The 
sections that follow describe these major findings, as well as 
other findings, according to each domain of the partnership 
framework. 
Context
Contextual factors such as critical events, existing relationships 
among potential partners, or politics, can facilitate or block 
the ability for a partnership to form and function effectively. 
When describing the HPV vaccine application partnership’s 
underlying context and history, respondents consistently 
mentioned past immunization partnership experiences, 
including that of the HPV demonstration project, the 
existence of champions, political priority around cervical 
cancer, and high levels of trust. 
Respondents noted that the partnership observed through 
this study started to form in 2013 with the application and 
introduction of PCV – the first engagement with Gavi since 
2005. A new team of UNEPI managers were appointed in 
2013, which respondents identified as having a positive 
influence in functioning of the partnership and on the timely 
submission of the HPV vaccine application.
“Originally, WHO and UNICEF were the major players but 
in recent years many more partners have come on board. 
The new EPI management has rejuvenated the partnership 
and all the partners come together under the EPI technical 
committee” (Development partner, 01).
This nascent partnership further evolved and strengthened 
through the HPV demonstration project, which resulted 
in positive working relationships between many of the 
stakeholders. 
Another contextual factor that strengthened the partnership 
was having a “champion” organization. As mentioned earlier, 
Uganda was one of the countries chosen by PATH to undertake 
the HPV vaccine project and as a result, respondents identified 
PATH as championing the application process and working 
behind the scenes to move the process along: 
“PATH played a critical role. PATH continued reminding 
MoH of the need to prioritize the HPV [vaccine] introduction” 
(Development partner, 01).






Average degree (ties) 2.8
Average tie weight (ie,  reported trust) 3.14
a These values are based on analysis of 11 completed network surveys, and 
thus, care must be taken in interpreting these values alone. Triangulation 
with other data sources provides a more reliable picture. 
Table 4. Perceived Benefits of Partnership (n = 11 Respondents 
Surveyed)
Benefits
% Of Respondents 
Who Agreed
Effectiveness
Planned activities are executed with greater quality 100
Better able to identify the need for, and to acquire 
additional support
90
Better able to respond to existing challenges, or 
those that arise during the process
90
Better able to execute introduction activities 78
Increases sustainability of immunization program 35
Mean (effectiveness) 79
Efficiency 
More timely execution of planned activities 80
Leverages each organization’s comparative 
advantages 
70
Reduction in financial cost of process 60





Increases country ownership 90
Increases legitimacy of decisions made 90
Increases fairness of decisions made 89
Increases transparency among partners 80
Increases accountability among partners 70
Mean (country ownership) 84
Drawbacks
Effectiveness
Creates competition and conflict among member 
organizations
0
Strained relations within my organization 0
Mean (effectiveness drawbacks) 0
Efficiency
Unnecessary management burden on my 
organization
38
Loss of control/autonomy over decisions 11
Forces us to make decisions in a way which is not 
natural/typical for our organization 
11
Mean (efficiency drawbacks) 20
Country ownership
Not enough credit given to my organization 25
Total (country ownership drawbacks) 25
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Qualitative data confirmed the survey finding related to 
high levels of trust in the network. Respondents typically 
reported trusting others they worked with, particularly if 
they had a history of working together. Trust was not always 
synonymous with perceptions of professional competence 
and low trust scores are clustered around technical assistance 
providers who were new to the Ugandan context. The trusting 
environment was also associated in interviews with country 
ownership, which was in contrast to the rushed process and 
lack of ownership in the subsequent IPV application process.
“The HPV partnership functioned in an environment of 
trust as mentioned in the survey. There was accountability, 
honesty and shared goals. If this trust did not exist, then the 
application process would not be successful” (Civil society 
organization, 02).
“Yes, the HPV application partnership facilitated country 
ownership of the process, especially when compared to IPV 
[application process]” (MoH, 03).
Buy-in and ownership was also attributed to the high levels 
of political will and priority surrounding HPV vaccine and 
cervical cancer. The First Lady of Uganda was a champion for 
HPV vaccine,46,47 and the issue (cervical cancer) was considered 
by respondents a reason for high partner involvement. 
Network Structure Informed Performance and Practices
Our analysis of the network data, confirmed by data from 
interviews and observation, indicates that the network 
structure displayed structural attributes consistent with other 
partnerships: relative decentralization; moderate density in 
the network core; and high average levels of trust (see Table 
3).20,21,48 However, network mapping also uncovered ‘missing’ 
actors. 
The network centralization score (0.40) indicates that there 
was no single leader in this network; although there is some 
tendency towards UNEPI, followed by WHO and UNICEF. 
This is illustrated in Figure 2 and is consistent with interview 
data attributing formal leadership to the MoH, but practical 
leadership support to other partners, including an advocacy 
role by PATH:
“The MoH took a lead in HPV application process… The 
government is currently taking the leading role in these 
processes unlike the past. However, PATH played a critical 
role. PATH continued reminding MoH of the need to 
prioritize the HPV [vaccine] introduction” (Development 
partner).
The network survey helped to identify who was involved, 
as well as who was not. Given that HPV vaccine is targeted 
to adolescent girls, and that UNEPI proposed to deliver the 
vaccine through school-based channels, the involvement 
of the Ministry of Education (MoE) should have been a 
necessary condition for application. Some respondents noted 
that the MoE did not attend application meetings, although 
their signature was on the application submitted to Gavi: 
“I didn’t see MoE during the application process. They 
participated in demonstration project but not the application 
process. We could have actually involved them much more 
but we just didn’t” (MoH, 05).
The absence of the MoE was an issue also raised by the Gavi 
Independent Review Committee (IRC) in their initial review 
of the application, but the Alliance Board ultimately approved 
the application. The absence of the MoE was also raised to 
the EPI program by the FCE team in Uganda, who acted to 
include the MoE in planning meetings once the application 
had been approved. As Uganda ultimately decided to deliver 
HPV vaccine through schools, their participation in the 
planning process was necessary. This study may have been 
one contributing factor to their involvement during planning, 
thus, mitigating potential consequences of their absence. 
The Gavi Senior Country Manager was not named. While on 
one hand their strong engagement is considered essential for 
Gavi’s success, it is also true that they are meant to provide 
support for effective implementation of, and not applications 
for, Gavi support. Only one individual from the Ministry of 
Finance (MoF) was named, once. The lack of participation 
from the finance ministry is consistent with other network-
based studies of new vaccine decision-making; a finding that 
is not always apparent from reviewing application documents 
alone.49 Participation of finance ministries in decision-
making is recommended as a means of ensuring financial 
sustainability. As Gavi-eligible countries begin to take on a 
larger share of vaccine co-financing and transition from Gavi 
support, there are concerns over the long-term financial 
sustainability of immunization programs.50,51 
Performance and Practices Facilitated Positive Outcomes
So far we have described a partnership that is based on 
trust and mutual understanding and structured to allow for 
shared decision-making across a wide range of actors. Yet 
supportive context and structure are not sufficient to lead 
to positive outcomes; how the partnership is managed in 
practice, and whether individuals fulfill their responsibilities 
and expectations will determine its ultimate effectiveness, 
efficiency, and country ownership. 
Numerous respondents noted that the HPV vaccine 
application partnership was not formalized in writing; 
no terms of reference existed to outline composition, 
roles, and responsibilities. Interviewers probed further on 
specific mechanisms intended to manage and coordinate 
immunization partnerships – the Gavi Business Plan and the 
Inter-agency Coordinating Committee (ICC) – but found they 
Figure 2. HPV Vaccine Application Partnership Network, Working 
Together Ties. Ties weighted by reported trust score, nodes sized by 
degree centrality and colored by organization type. Abbreviations: 
MoH, Ministry of Health; CSO, civil society organization; NGO, non-
governmental organization.
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had not played their intended roles. The Gavi Business Plan 
outlined Alliance partners’ roles and responsibilities for Gavi 
activities in each country but few respondents were aware of 
its existence, and thus, which partners were assigned to which 
specific activities supporting HPV vaccine introduction. The 
ICC is a national policy advisory committee for immunization 
that is meant to coordinate partner roles and endorse all Gavi-
related decisions, but it was implicated as a final decision-
taking body as opposed to one coordinating work processes, 
roles, or responsibilities across partners. 
Respondents differed on the consequences of this for the 
process; some spoke favorably of the way in which roles 
were assigned on an as-needed basis. Others found that the 
process would have been improved if roles were assigned at 
the beginning. As a result, some respondents noted that some 
partners were more involved than others. 
The consequences of the management issues are perhaps best 
reflected by whether respondents considered the partnership 
to have benefitted effectiveness, efficiency, or country 
ownership. As noted above, the statements that were met 
with the highest level of agreement were on average related 
to country ownership and effectiveness, and then efficiency 
(see Table 4). 
While the country ownership outcome scored high overall, 
only 35% of respondents thought the partnership improved 
the overall sustainability of the immunization program. A 
highly functioning HPV vaccine application partnership 
should add value not only to the HPV vaccine application 
process, but also to Uganda’s broader EPI program. 
Discussion
As expected, an immunization partnership existed around 
the HPV vaccine application process for Gavi support, and 
the partnership was perceived positively in terms of perceived 
country ownership and effectiveness but slightly less so for 
efficiency. This study suggests three key drivers of partnership 
added value: trust; a diverse and inclusive network; and a clear 
governance mandate.
A key finding was the importance of trust in facilitating the 
effective functioning of this partnership. Trust existed because 
of underlying relationships among the network actors, built 
in part by previous new vaccine introductions and through 
the HPV vaccine demonstration project. Trust matters; as 
the Alliance moves forward with the implementation of 
new forms of country-targeted technical assistance through 
the Partners’ Engagement Framework, they should remain 
sensitive to the need to build trust between and within all 
Alliance partners, including governments. 
Our second major finding is related to inclusiveness. On one 
hand, the absence of the education and finance ministries had 
the potential to lead to inefficiencies during implementation 
as their specific knowledge was and is necessary for effective, 
efficient, and sustainable implementation of the HPV vaccine. 
In part due to this study and the broader FCE, the MoH 
ensured the participation of the MoE during the vaccine 
introduction planning process, ensuring a smooth roll-out of 
a school-based delivery program. The under-representation 
of finance ministry staff in vaccine policy decision-making 
is a persistent issue which must be systematically addressed 
if long-term programmatic and financial sustainability is to 
be achieved. 
On the other hand, the network was otherwise diverse and 
inclusive. The composition of the network extended far 
beyond the Alliance’s ‘core partners’ and demonstrates the 
utility of empirically mapping such networks. Consistent 
with partnership principles and network theory, diverse 
actors ultimately improve the innovativeness and resilience 
of a network through their ability to access new ideas and 
resources. In this case, an NGO partner was instrumental 
in maintaining momentum during the process. However, 
despite the relative diversity of this network, we note that the 
network sub-core consists of relatively few individuals, and 
that the departure of even one could cause major delays or 
inefficiencies. 
Our third driver of partnership added value is clear governance 
and management structure and processes. Compared to the 
other outcomes, respondents did not find the partnership 
efficient. Eighty-four percent of respondents perceived the 
partnership increased country ownership, compared to 
79% considering it to have improved effectiveness, and 63% 
thought it improved efficiency. The principles that define 
partnerships, namely shared goals, and decentralized, diverse 
actors, simultaneously create governance and management 
challenges. This is particularly true in mandated, versus 
emergent, networks,20 such as the Alliance and most other 
global health partnerships. 
Perceived efficiency and overall governance of the partnership 
could be improved while retaining its legitimacy. Specifically, 
this partnership did not report many standardized or 
formalized procedures or management mechanisms. While 
the relative lack of formalized rules and procedures enabled 
flexibility on one hand, we recommend that national 
immunization partnerships be strengthened to provide a 
clear governance and management structure and to clarify 
and coordinate partner roles and responsibilities. Reaffirming 
the central leadership roles of the EPI program — and 
strengthening their capacity to govern and manage — will 
ensure that good governance occurs while also strengthening 
country ownership. 
Reflections on the Partnership Framework
This case study was driven by the partnership analytic 
framework.18 We see tremendous added value of applying a 
theoretical framework to inform study design, data collection, 
and data analysis and to contribute to theory-driven health 
policy and systems research.52,53 The partnership framework 
domains (context, structure, partner practices, partnership 
performance, and outcomes) were highly sensitive and 
specific to the data we collected, and this framework could be 
applicable to a variety of cases unrelated to Gavi support. We 
built on the framework’s intended qualitative data collection 
approach with the use of social network mapping in order to 
empirically measure who truly worked in the partnership, and 
the measurable structure and strength of their relationships. 
Without the network survey, we might not have realized 
the extent to which the ministries of education and finance 
were absent from the process, which has had mid-range 
consequences on the ongoing HPV vaccine planning process. 
Conversely, the network survey identified key non-traditional 
Gavi partners who were not named on the application, but 
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yet played an important role in Uganda’s process. This finding 
may help Uganda’s EPI program as it considers partnership 
needs and ideal partners for ongoing and future immunization 
activities. 
Our findings also highlight the benefits of the prospective 
evaluation approach to identify downstream consequences 
of partnership processes. However, and particularly in an 
ongoing, prospective evaluation where respondent burden 
and fatigue is of particular concern, the data-heavy needs 
of SNA are difficult to achieve. We recommend ongoing 
experimentation with secondary sources of network data, 
including meeting attendance, to reduce respondent burden 
while simultaneously leveraging the power of network science. 
The new Partners’ Engagement Framework will potentially 
improve the transparency and accountability of partners 
and increase country ownership by involving countries in 
the identification of their technical assistance needs from 
partners. However, this study showed that the existence of 
many capable partners does not ensure clear expectations and 
management of activities and processes. Ongoing evaluations 
should track the impact of PEF on partnership networks and 
their outcomes. 
Strengths and Limitations
Our choice of the HPV vaccine application case was for 
pragmatic and theoretical reasons. The fact that HPV vaccine 
is likely to require new or different partners as compared to 
childhood vaccines may limit the external generalizability of 
our findings. On the other hand, this same particularity makes 
it a very relevant case study to inform the implementation 
and evaluation of the Partners’ Engagement Framework, 
which will likely bring many new partners into established 
partnerships. This study was cross-sectional, which means 
that the network data do not represent the partnership 
dynamics that certainly exist. 
Only 11 network surveys were administered, in part to mitigate 
respondent burden within the context of a 4-year prospective 
evaluation. Network data collection is notoriously difficult 
due to the need to survey the census of the network, but not 
impossible with adequate time commitment and a supportive 
context.36 This study’s low response rate limits the internal and 
external validity of the reported SNA measures; however, we 
have taken great care to present quantitative network findings 
which were supported by data from qualitative interviews 
and participant observation. While our data likely provide a 
more accurate representation of the structure of the network 
core, we caution that the periphery structure, particularly its 
density, will be underestimated based on missing ties between 
non-interviewed nodes. While we measured respondents’ 
perceptions of the partnership’s effectiveness, efficiency, and 
country ownership during the study, the prospective nature 
of the Gavi Full Country Evaluation enabled the inclusion of 
evidence on the mid-term outcomes of the HPV application 
process and the national implementation of HPV vaccine. 
Conclusion
Despite the particularities of an HPV vaccine partnership, 
these data and findings can serve as a baseline from which 
to compare the effects of the new Partners’ Engagement 
Framework and whether that policy change increases 
effectiveness, efficiency and country ownership. This study 
offers a number of important lessons for the design and 
implementation of the Partners’ Engagement Framework; 
notably that the quality of relationships matters when 
considering new partners, and that without clear roles, 
responsibilities, and terms of references, adding new partners 
is only likely to decrease efficiency further. Further efforts to 
test the partnership framework should ultimately lead to clear 
recommendations for governments and partners outlining 
how to best structure and manage partnerships to achieve 
critical global health goals. 
The partnership framework and approach presented here can 
be applied to measure the health and performance of other 
global health partnerships to ensure that they are meeting 
the complex challenges they are designed to address. As 
partnerships become an increasingly common approach to 
health and development, it is important to ensure they are 
performing optimally and intervene when they are not. The 
partnership framework combines SNA and partnership theory 
into a single useful and adaptable framework that evaluators 
or policy-makers can apply to understand and intervene to 
strengthen networks, to ultimately improve global health 
more effectively, efficiently, and legitimately. 
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